Clinical Trials Browser

Phase 1/2 × repotrectinib × 90 days × Clear all

NCT05004116 2026-03-04

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis